Equities research analysts forecast that Opiant Pharmaceuticals Inc (NASDAQ:OPNT) will post ($0.32) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Opiant Pharmaceuticals’ earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.36). Opiant Pharmaceuticals also reported earnings of ($0.32) per share in the same quarter last year. The business is expected to report its next quarterly earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Opiant Pharmaceuticals will report full-year earnings of $0.40 per share for the current year, with EPS estimates ranging from ($1.30) to $2.05. For the next year, analysts expect that the company will post earnings of $0.26 per share, with EPS estimates ranging from ($3.55) to $4.07. Zacks’ EPS averages are an average based on a survey of research firms that cover Opiant Pharmaceuticals.

Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its earnings results on Thursday, August 8th. The technology company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.86. Opiant Pharmaceuticals had a negative net margin of 11.78% and a negative return on equity of 12.82%. The business had revenue of $6.78 million for the quarter, compared to analyst estimates of $3.91 million.

OPNT has been the topic of several recent analyst reports. ValuEngine raised shares of Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 6th. Northland Securities reissued a “buy” rating on shares of Opiant Pharmaceuticals in a research note on Friday, August 2nd.

Shares of OPNT stock traded up $0.74 during mid-day trading on Tuesday, hitting $15.90. 33,154 shares of the stock were exchanged, compared to its average volume of 21,134. The stock’s fifty day moving average price is $13.03. Opiant Pharmaceuticals has a 52-week low of $9.98 and a 52-week high of $29.55. The company has a market capitalization of $61.99 million, a P/E ratio of -2.24 and a beta of 0.43.

In related news, insider Phil Skolnick sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $11.60, for a total transaction of $116,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 30,000 shares of company stock worth $365,000. Corporate insiders own 30.88% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in OPNT. Advisor Group Inc. lifted its stake in shares of Opiant Pharmaceuticals by 24.3% during the second quarter. Advisor Group Inc. now owns 4,600 shares of the technology company’s stock valued at $61,000 after buying an additional 900 shares during the period. BlackRock Inc. lifted its stake in shares of Opiant Pharmaceuticals by 44.0% during the fourth quarter. BlackRock Inc. now owns 10,259 shares of the technology company’s stock valued at $149,000 after buying an additional 3,137 shares during the period. Spark Investment Management LLC lifted its stake in shares of Opiant Pharmaceuticals by 17.6% during the first quarter. Spark Investment Management LLC now owns 15,100 shares of the technology company’s stock valued at $198,000 after buying an additional 2,265 shares during the period. Granite Investment Partners LLC purchased a new position in shares of Opiant Pharmaceuticals during the first quarter valued at approximately $356,000. Finally, Northern Trust Corp lifted its stake in shares of Opiant Pharmaceuticals by 3.5% during the fourth quarter. Northern Trust Corp now owns 41,803 shares of the technology company’s stock valued at $604,000 after buying an additional 1,398 shares during the period. 18.60% of the stock is currently owned by institutional investors and hedge funds.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Further Reading: What is a Futures Contract?

Get a free copy of the Zacks research report on Opiant Pharmaceuticals (OPNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.